Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21539908 | 0.94 | CYP1A2 (0.40) | PRMT6P2RY12CYP1A2ABL1RIN1 | |
| SCHEMBL20428124 | 0.91 | P2RY12 (0.40) | PRMT6P2RY12CYP1A2ABL1RIN1 | |
| SCHEMBL19146295 | 0.88 | PRMT6 (0.38) | PRMT6P2RY12CYP1A2ABL1RIN1 | |
| SCHEMBL21376284 | 0.86 | P2RY12 (0.40) | PRMT6P2RY12CYP1A2ABL1RIN1 | |
| SCHEMBL20353076 | 0.85 | P2RY12 (0.45) | P2RY12ABL1RIN1 | |
| SCHEMBL24444139 | 0.85 | ADORA1 (0.43) | PRMT6P2RY12CYP1A2ADORA1 | |
| SCHEMBL19146392 | 0.84 | P2RY12 (0.42) | PRMT6P2RY12CYP1A2ABL1RIN1 | |
| SCHEMBL20026293 | 0.84 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL23621388 | 0.84 | P2RY12 (0.44) | PRMT6P2RY12CYP1A2ABL1RIN1 | |
| SCHEMBL19145868 | 0.83 | P2RY12 (0.40) | PRMT6P2RY12ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | KAYLA THERAPEUTICS (FR) | 2021-07-06 | — | — | US | disclosed |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | KAYLA THERAPEUTICS (FR) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053272-B2 | Cyclic dinucleotides for cytokine induction | IL1B, IFNG, IFNAR1 | PRMT6 1821/4885P2RY12 908/4885CYP1A2 1626/4885 |
| US-20200255469-A1 | CYCLIC DINUCLEOTIDES FOR CYTOKINE INDUCTION | IL1B, IFNG, IFNAR1 | PRMT6 1821/4885P2RY12 908/4885CYP1A2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.